Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

4.9K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.9K
Analgesia and Pain Management01:25

Analgesia and Pain Management

2.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.1K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.2K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.2K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.1K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.1K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Analysis of Organic Liquid Three-Component Systems: Near-Infrared Transmission versus Raman Spectroscopy, Partial Least Squares versus Classical Least Squares Regression Evaluation and Volume versus Weight Percent Concentration Units.

Molecules (Basel, Switzerland)·2019
Same author

microRNA-221 restricts human cytomegalovirus replication via promoting type I IFN production by targeting SOCS1/NF-κB pathway.

Cell cycle (Georgetown, Tex.)·2019
Same author

Hydrogen bonding derived self-healing polymer composites reinforced with amidation carbon fibers.

Nanotechnology·2019
Same author

Comparative analysis of the main active constituents from different parts of Leonurus japonicus Houtt. and from different regions in China by ultra-high performance liquid chromatography with triple quadrupole tandem mass spectrometry.

Journal of pharmaceutical and biomedical analysis·2019
Same author

The Comprehensive Evaluation of Safflowers in Different Producing Areas by Combined Analysis of Color, Chemical Compounds, and Biological Activity.

Molecules (Basel, Switzerland)·2019
Same author

The DNA-binding mechanism of the TCS response regulator ArlR from Staphylococcus aureus.

Journal of structural biology·2019

Related Experiment Video

Updated: Feb 17, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

9.2K

ABIN-1 Negatively Regulates μ-Opioid Receptor Function.

Peilan Zhou1, Jiebing Jiang2, Hui Yan2

  • 1State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing, China ruibinsu@126.com zhoupeilan0502@sina.com.

Molecular Pharmacology
|December 15, 2017
PubMed
Summary

A20-binding inhibitor of nuclear factor kappa B (ABIN-1) negatively regulates the mu-opioid receptor (MOR) in vitro and in vivo. ABIN-1 inhibits MOR activation, phosphorylation, and internalization, impacting pain and reward pathways.

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.8K
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K

Related Experiment Videos

Last Updated: Feb 17, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

9.2K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.8K
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • The mu-opioid receptor (MOR) is a key G protein-coupled receptor involved in pain, reward, and euphoria.
  • Understanding MOR regulation is crucial for developing targeted therapeutics.
  • A20-binding inhibitor of nuclear factor kappa B (ABIN-1) is implicated in inflammatory signaling pathways.

Purpose of the Study:

  • To investigate the interaction between ABIN-1 and MOR.
  • To determine the functional consequences of this interaction on MOR signaling and cellular trafficking.
  • To assess the in vivo relevance of ABIN-1 in MOR regulation.

Main Methods:

  • Bacterial two-hybrid screening to identify interacting proteins.
  • Coimmunoprecipitation and direct protein-protein binding assays to confirm MOR-ABIN-1 interaction.
  • Cellular assays in Chinese hamster ovary (CHO) cells to measure G protein activation, adenylyl cyclase activity, and extracellular signal-regulated kinase (ERK) activation.
  • Zebrafish larvae model with antisense morpholino oligonucleotide (MO) gene knockdown to assess in vivo effects of ABIN-1 on morphine-induced hyperlocomotion.

Main Results:

  • ABIN-1 directly binds to the carboxyl tail of MOR.
  • ABIN-1 inhibits DAMGO-induced G protein activation, MOR phosphorylation, ubiquitination, and internalization.
  • ABIN-1 suppresses DAMGO-mediated inhibition of forskolin-stimulated adenylyl cyclase and negatively regulates ERK activation.
  • ABIN-1 knockdown in zebrafish larvae significantly enhances morphine-induced hyperlocomotion.

Conclusions:

  • ABIN-1 acts as a negative coregulator of MOR activation, phosphorylation, and internalization in vitro.
  • ABIN-1 modulates MOR function in vivo, impacting behavioral responses to morphine.
  • These findings reveal a novel regulatory mechanism for MOR signaling with potential therapeutic implications.